Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Mar 06, 2014 2:24pm
209 Views
Post# 22290448

RE:RE:Quiet board

RE:RE:Quiet boardWhile I would agree with the obvious fact that there has been more sellers than buyers as of late, to say that the "smart money got out in the $.80's" is a bit of a stretch given that the average transaction price since January 16th, the day after buyers stepped in on news, only approaches 80 cents. The TOTAL cdn volume has been only roughly 2.4 million shares, not much for smart money, which to me would more indicate that people have traded out of some of their position looking for a pullback and a better re-entry but not willing to exit completely.  I know that's what I did.  Maybe I'm being a little picky here but it just seems the statement is overly bearish given the facts.

I would agree that management, as usual, seems to be very inefficient and that something needs to get done fairly quickly.  I sometimes wonder if part of any negotiations that might be taking place might be a bit stuck on the fact that if RVX is successful at obtaining gov't support for the Alzheimers program that will make the overall RVX program more valuable.  Management would want this taken into consideration while a potential suitor would probably want to ignore this given it's not occurred yet and likely won't occur until after RVX needs more funding.  Just some thoughts....... 


Bullboard Posts